Zenlabs Ethica (BOM:530697) Piotroski F-Score: 4 (As of Jul. 04, 2026) — 20% Below Median


BOM:530697 Zenlabs Ethica Ltd BOM:530697
53 GF Score
Price ₹35.80
GF Value ₹29.35
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Zenlabs Ethica Piotroski F-Score?

Zenlabs Ethica BOM:530697 +0.93% 53 Piotroski F-Score is 4 as of Jul. 04, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates BOM:530697 with a GF Score™ of 53/100 and a GF Value™ of ₹29.35 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 112 Medical Distribution companies, Zenlabs Ethica ranks worse than 62.5% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zenlabs Ethica has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Zenlabs Ethica's Piotroski F-Score or its related term are showing as below:

BOM:530697' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Zenlabs Ethica was 8. The lowest was 3. And the median was 5.

Zenlabs Ethica  (BOM:530697) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Zenlabs Ethica Piotroski F-Score Related Terms


Zenlabs Ethica Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Zenlabs Ethica's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenlabs Ethica Piotroski F-Score Chart

Zenlabs Ethica Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 5.00 6.00 4.00

Zenlabs Ethica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 0.00 0.00 0.00 4.00

BOM:530697 vs MCK, CAH, COR: Piotroski F-Score Comparison

For the Medical Distribution subindustry, Zenlabs Ethica's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenlabs Ethica Piotroski F-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Zenlabs Ethica's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Zenlabs Ethica's Piotroski F-Score falls into.


BOM:530697
53GF Score
Zenlabs Ethica Ltd BOM:530697
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹-19.4 Mil.
Cash Flow from Operations was ₹40.6 Mil.
Revenue was ₹469.2 Mil.
Gross Profit was ₹129.3 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (406.222 + 372.064) / 2 = ₹389.143 Mil.
Total Assets at the begining of this year (Mar25) was ₹406.2 Mil.
Long-Term Debt & Capital Lease Obligation was ₹4.8 Mil.
Total Current Assets was ₹351.0 Mil.
Total Current Liabilities was ₹271.2 Mil.
Net Income was ₹2.7 Mil.

Revenue was ₹514.2 Mil.
Gross Profit was ₹142.0 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (402.584 + 406.222) / 2 = ₹404.403 Mil.
Total Assets at the begining of last year (Mar24) was ₹402.6 Mil.
Long-Term Debt & Capital Lease Obligation was ₹5.7 Mil.
Total Current Assets was ₹373.5 Mil.
Total Current Liabilities was ₹281.2 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zenlabs Ethica's current Net Income (TTM) was -19.4. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zenlabs Ethica's current Cash Flow from Operations (TTM) was 40.6. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-19.356/406.222
=-0.04764882

ROA (Last Year)=Net Income/Total Assets (Mar24)
=2.692/402.584
=0.0066868

Zenlabs Ethica's return on assets of this year was -0.04764882. Zenlabs Ethica's return on assets of last year was 0.0066868. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Zenlabs Ethica's current Net Income (TTM) was -19.4. Zenlabs Ethica's current Cash Flow from Operations (TTM) was 40.6. ==> 40.6 > -19.4 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=4.821/389.143
=0.01238876

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=5.683/404.403
=0.01405281

Zenlabs Ethica's gearing of this year was 0.01238876. Zenlabs Ethica's gearing of last year was 0.01405281. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=350.962/271.168
=1.29426038

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=373.482/281.227
=1.3280446

Zenlabs Ethica's current ratio of this year was 1.29426038. Zenlabs Ethica's current ratio of last year was 1.3280446. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Zenlabs Ethica's number of shares in issue this year was 6.517. Zenlabs Ethica's number of shares in issue last year was 6.566. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=129.261/469.225
=0.27547765

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=142.008/514.225
=0.27615927

Zenlabs Ethica's gross margin of this year was 0.27547765. Zenlabs Ethica's gross margin of last year was 0.27615927. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=469.225/406.222
=1.155095

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=514.225/402.584
=1.27731107

Zenlabs Ethica's asset turnover of this year was 1.155095. Zenlabs Ethica's asset turnover of last year was 1.27731107. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zenlabs Ethica has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Zenlabs Ethica (BOM:530697) has a Piotroski F-Score of 4 as of Jul. 04, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zenlabs Ethica and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Zenlabs Ethica's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Zenlabs Ethica ranks #70 out of 112 companies in the Medical Distribution industry, placing it in the top 62.5%.
Is Zenlabs Ethica's Piotroski F-Score too high?
Zenlabs Ethica's current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Medical Distribution industry median Piotroski F-Score is 5.00. Zenlabs Ethica's value of 4 is 20% below this industry median. Based on the distribution chart, Zenlabs Ethica ranks #70 out of 112 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Zenlabs Ethica has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zenlabs Ethica's Piotroski F-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Zenlabs Ethica ranks #70 out of 112 companies for Piotroski F-Score. This places Zenlabs Ethica in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Zenlabs Ethica's value of 4 is 20% below this benchmark. Historically, Zenlabs Ethica's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Zenlabs Ethica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenlabs Ethica's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zenlabs Ethica and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenlabs Ethica's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenlabs Ethica stock overvalued right now?
Based on GuruFocus' analysis, Zenlabs Ethica (BOM:530697) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹29.35, compared to a current price of ₹35.80 — trading 22% above its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Medical Distribution industry median of 5.00. Zenlabs Ethica's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Zenlabs Ethica (BOM:530697), the current Piotroski F-Score is 4 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zenlabs Ethica (BOM:530697) Overvalued in 2026?

Based on GuruFocus' analysis, Zenlabs Ethica stock appears to be overvalued. The current stock price of ₹35.80 is trading 22% above its estimated GF Value™ of ₹29.35. GuruFocus considers Zenlabs Ethica to be Modestly Overvalued.

Key valuation signals for BOM:530697:

  • Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
  • GF Value™: ₹29.35 vs. price of ₹35.80 (22% above fair value)
  • GF Score™: 53/100 with 3 warning signs
  • Industry Position: 20% below the Medical Distribution median (#70 of 112)

No single metric tells the full story. See the BOM:530697 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zenlabs Ethica Business Description

Address Plot No.194-195, 3rd Floor, Industrial Area, Phase-II, Ram Darbar, Chandigarh, IND, 160002
Zenlabs Ethica Ltd is a pharmaceutical company engaged in the trading of pharmaceutical formulations. It manufactures and markets drugs which include Gastrointestinal disorders, anti-diabetics, anti-hypertensive drugs, anti-infective, soaps, and anti-Bacterial drugs, nutraceuticals, and others. In addition, The company offers more than 600 products across therapeutic segments.
53GF Score

Get the complete analysis for BOM:530697

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹35.80
Price
₹29.35
GF Value